Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
BIOMARKER:
KDR overexpression
i
Other names:
KDR, CD309, FLK1, VEGFR, VEGFR2, Kinase insert domain receptor (a type III receptor tyrosine kinase)
Associations
(9)
News
Trials
C3 | Sensitive
C4 | Sensitive
D | Sensitive
C3 | Resistant
C4 | Resistant
D | Resistant
Show legend
Include preclinical:
Drug categories
EGFR
Tyrosine Kinase Inhibitors
CD Protein Inhibitors
Immune Checkpoint Inhibitors
Immunotherapy
Cancel
Non Small Cell Lung Cancer
Nasopharyngeal Carcinoma
Breast Cancer
Hepatocellular Cancer
Osteosarcoma
Renal Cell Carcinoma
Glioblastoma
anlotinib
C3
KDR overexpression
|
Osteosarcoma
|
anlotinib
camrelizumab + rivoceranib
C3
KDR overexpression
|
Nasopharyngeal Carcinoma
|
camrelizumab + rivoceranib
sunitinib
C4
KDR overexpression
|
Breast Cancer
|
sunitinib
D
KDR overexpression
|
Renal Cell Carcinoma
|
sunitinib
bevacizumab + atezolizumab
C3
KDR overexpression
|
Hepatocellular Cancer
|
bevacizumab + atezolizumab
Immunotherapy
C3
KDR overexpression
|
Non Small Cell Lung Cancer
|
Immunotherapy
bevacizumab
C3
KDR overexpression
|
Glioblastoma
|
bevacizumab
bevacizumab + erlotinib
C3
KDR overexpression
|
Glioblastoma
|
bevacizumab + erlotinib
pembrolizumab
C3
KDR overexpression
|
Non Small Cell Lung Cancer
|
pembrolizumab
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
